Business News • MarketWire • The European Patent Office Grants MolMed a New Patent on Its Anticancer Drug NGR-hTNF |
The European Patent Office Grants MolMed a New Patent on Its Anticancer Drug NGR-hTNF |
|
|
The European Patent Office Grants MolMed a New Patent on Its Anticancer Drug NGR-hTNF
MILAN, ITALY--(Marketwire - June 18, 2012) - MolMed S.p.A. (MILAN:MLM) announces today that it received the official notification from the European Patent Office of the decision to grant a patent covering the therapeutic use of its investigational anticancer drug NGR-hTNF for the treatment of mesothelioma, a pleural cancer caused by exposure to asbestos. The grant will take effect on 4 July 2012, when it will be published in the European Patent Bulletin. NGR-hTNF is currently being investigated in the only ongoing Phase III trial for relapsed mesothelioma, as well as in a randomised Phase II trial as first line maintenance therapy for mesothelioma patients who completed the standard chemotherapy.
View More : http://www.marketwire.com/mw/release.do?id=1670210&sourceType=3
|
|
|